TickerFacts.

Company research / YBGJ

Yubo International Biotech Ltd (YBGJ)

Build a valuation ↗↓ Download CSV

CIK 0000895464 · OTC · Electromedical & Electrotherapeutic Apparatus

  • Sector Manufacturing
  • Incorporated NY
  • Fiscal year ends around Dec 31

For the year ended 2025-12-31, Yubo International Biotech Ltd reported revenue of $12.4K. Revenue grew 256.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $12.4K.

Key ratios (year ended 2025-12-31)

66.1%
Gross margin
n/m
Operating margin
n/m
Net margin
256.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-14

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312020-02-292019-02-282018-02-282017-02-28
Revenue$12.4K$12.4K$3.5K$604.7K$104.3K$1.24Mn/a$0$0$0$0
Cost of Revenue$4.2K$4.2K$822$185.5K$51.6K$423.7K$114.3Kn/an/an/an/a
Gross Profit$8.2K$8.2K$2.6K$419.2K$52.7K$820.6K$1.24Mn/an/an/an/a
Operating Income-$1.12M-$1.19M-$1.77M-$1.19M-$1.21M-$1.54M-$711.8K-$29.0K-$48.0K-$58.0K-$149.0K
Depreciation & Amortization$111.1K$167.6K$169.9K$178.3K$18.1K$13.2K$13.1Kn/an/an/an/a
EBITDA-$1.01M-$1.02M-$1.60M-$1.02M-$1.19M-$1.53M-$698.7Kn/an/an/an/a
Net Income-$1.06M-$1.08M-$1.78M-$1.20M-$1.20M-$1.54M-$711.8K-$134.0K-$148.0K-$144.0K-$224.0K
EPS (Diluted)n/a-$0.01-$0.02-$0.10n/an/an/an/an/an/an/a
Total Assets$672.3K$847.1K$1.53M$1.67M$2.35M$4.59M$2.44M$1.0K$4.0Kn/an/a
Total Liabilities$3.33M$2.79M$4.83M$3.51M$2.91M$4.72M$1.28Mn/an/an/an/a
Shareholders' Equity-$2.62M-$1.95M-$3.42M-$1.84M-$565.4K-$131.2K$1.17M-$1.80M-$1.66M-$1.52M-$1.37M
Cash & Equivalents$12.0K$8.1K$7.0K$6.4K$18.2K$27.5K$1.38M$1.0K$4.0K$2.0K$1.0K
Operating Cash Flown/a-$842.8K-$1.34M-$739.0K-$601.0K-$1.02M$101.1K-$22.0K-$32.0K-$55.0K-$55.0K
Capital Expendituresn/an/an/an/a$0$564.7K$42.6Kn/an/an/an/a
Free Cash Flown/an/an/an/a-$601.0K-$1.59M$58.6Kn/an/an/an/a
Weighted Average Diluted Sharesn/a139.64M119.82M11.98Mn/an/an/an/an/an/an/a